Table 4

Univariate Cox regression analysis for B, E, R, T RQ values according to progression free and overall survival
aberrant vs. normal Progression free survival Overall survival
Total N Events HR 95% C.I. Wald’s p Total N Events HR 95% C.I. Wald’s p
Subgroup A BRCA1 51 vs. 100 44 vs. 79 1.307 0.901-1.897 0.158 51 vs. 102 35 vs. 62 1.019 0.672-1.545 0.930
ERCC1 43 vs. 110 36 vs. 88 1.224 0.829-1.806 0.309 44 vs. 111 30 vs. 68 1.169 0.760-1.799 0.478
RRM1 58 vs. 95 49 vs. 75 1.348 0.936-1.939 0.108 59 vs. 96 42 vs. 56 1.141 0.760-1.715 0.524
TYMS 78 vs. 75 63 vs. 61 0.849 0.593-1.216 0.373 79 vs. 76 50 vs. 48 0.871 0.583-1.302 0.500
Subgroup B BRCA1 58 vs. 113 49 vs. 87 1.313 0.921-1.872 0.132
ERCC1 50 vs. 123 41 vs. 96 1.251 0.867-1.805 0.232
RRM1 66 vs. 107 55 vs. 82 1.371 0.971-1.935 0.073
TYMS 87 vs. 86 68 vs. 69 0.922 0.656-1.297 0.642
Subgroup C BRCA1 62 vs. 123 38 vs. 67 1.003 0.672-1.499 0.987
ERCC1 53 vs. 134 32 vs. 74 1.02 0.672-1.548 0.926
RRM1 73 vs. 114 45 vs. 61 1.059 0.718-1.562 0.772
TYMS 95 vs. 92 56 vs. 50 1.027 0.699-1.509 0.892

Subgroup A: 1st line, chemo-naïve; Subgroup B: 1st line, chemo-naïve and pre-treated; Subgroup C: chemo-naïve, 1st line and non-relapsed adjuvant; empty cells: not-applicable.

Kotoula et al.

Kotoula et al. BMC Cancer 2012 12:342   doi:10.1186/1471-2407-12-342

Open Data